Pulled back right to the .618 fib, consolidated then broke the triangle to flag to next fib up monitoring for continuation, targeting 8$ area
Shares of $SEEL skyrocketed today after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos' closing price on Thursday. BTIG analyst Robert Hazlett likes the prospects for Seelos' pipeline. Last week, the biotech announced that it had completed enrollment in a pivotal proof-of-concept...
Retrace of rally to 68%. Sell volume went low. Forming an DOJI as sign of reversal.
Greetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, do not be hesitant to send us message (inbox). Our Service : Signal recomendation, Trading Course, Portofolio Consultation for multi asset such as Stock, FX,...
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...
After hours mover on good volume. Stock was set up for a reversal . Potential trade between the daily resistance levels as per the chart . High risk and volatile stock.
After Bouncing round on it's bottom for a little over 11 years, SEEL broke above the 21 MA, and formed a bullish flag, along with a golden cross. This has happened before in the past, but I think SEEL was before it's time. The US now has a new administration, and it's pro for a few things. Some most people would know is cannabis, but there's also another...
SEEL longer term view shows signs of reversal indicated by Head and shoulders pattern
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio includes late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New...
Could go as low as 0.76 in wedge but buying heavy at 0.96 as a bottom confirmation. Once break out of triangle, will look to test original price move resistance in 2.80's. Cup and handle target gives this number.